TUSTIN, Calif., Aug. 21 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL) announced today that for the three-month period ended June 30, 2007 the Company had net revenues of $2,413,501, an approximate increase of 69% over the first quarter of 2007. The Company had gross profits of $1,151,452 and incurred a net loss of ($2,264,305). Included in the loss were non-cash expenses of approximately $2,074,112 for depreciation, common stock, warrants and options issued.
Gary Dreher, CEO of AMDL stated that, "We are pleased by the significant growth of AMDL's business. AMDL's subsidiary Jade Pharmaceutical, Inc, (JPI) continues to grow its marketing and sales in the excellent Chinese marketplace. These activities position JPI for near-term increased sales growth, particularly during the second half of 2007."
AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. ("JPI"), is an international biopharma company. AMDL together with JPI, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. More information about AMDL and its products can be obtained at http://www.amdl.com.
About Jade Pharmaceutical:
JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.
Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
Contact: AMDL, Inc.
Mr. Paul Knopick
AMDL Investor Relations
Direct Line: 949.707.5365
|SOURCE AMDL, Inc.|
Copyright©2007 PR Newswire.